Multiple Biomarkers in Undiagnosed Pleural Effusion
Multiple Biomarkers in Undiagnosed Pleural Effusion
The purpose of this clinical trial is to evaluate the ability of various biomarkers measured
 in serum and/or pleural fluids to estimate the risk of finding cancer in patients with
 undiagnosed pleural effusions. An algorithm for prediction of the risk of finding cancer in
 the patient using an optimal combination of markers will be developed, and patients will be
 categorized as having a low, moderate, or high risk of finding cancer that might be used to
 more effectively triage patients.
Approximately 1.6 million cases of pleural effusion are seen in the US per year, with
 ~210,000 of those cases due to underlying malignancy. Pleural fluids have traditionally been
 divided into two types: transudative and exudative. The most common causes of transudative
 pleural effusion are congestive heart failure and cirrhosis. Common causes of exudative
 pleural effusion include malignancy, pneumonia, pulmonary embolism and viral infection. One
 study found that 42% of all exudative effusions were due to malignancy, and another found
 that malignancy was the underlying cause of 24% of all effusions. Differential diagnosis of
 the various causes of effusions is complex and includes gross appearance of the pleural fluid
 (PF), differential cell count, cytology, glucose and LDH levels, and sometimes adenosine
 deaminase (ADA) levels. In addition, spiral CT scans, bronchoscopy, thoracoscopy, needle
 biopsy of the pleura, and video assisted thoracoscopy (VATS) are all utilized to determine
 the underlying cause of pleural fluid accumulation. These procedures are expensive and may be
 traumatic to patients. In approximately 20% of patients presenting with pleural fluid
 accumulation, no underlying cause will be established. Despite promising results published in
 peer-reviewed journals over the last two decades, serum biomarkers have not gained acceptance
 as a standard of care in the management of patients with lung cancer, mesothelioma, or
 pleural effusion. The purpose of this clinical trial is to evaluate the ability of various
 biomarkers measured in serum and/or pleural fluids to estimate the risk of finding cancer in
 patients with undiagnosed pleural effusions. An algorithm for prediction of the risk of
 finding cancer in the patient using an optimal combination of markers will be developed, and
 patients will be categorized as having a low, moderate, or high risk of finding cancer that
 might be used to more effectively triage patients. For example, a high risk of cancer may be
 used to justify more invasive or expensive procedures, such as spiral CT scans and
 thoracoscopy.

 This is a prospective, multi-center, double-blind, statistically powered clinical trial that
 will enroll patients scheduled to undergo a procedure for removal of fluid from a pleural
 effusion (i.e. thoracentesis, thoracoscopy, image guided thoracentesis, thoracotomy, chest
 tube placement, Pleurex® catheter insertion, etc.).

 The primary objective of the study is to evaluate the ability of multiple biomarkers in serum
 and/or pleural fluid to estimate the risk of finding cancer in subjects presenting with an
 undiagnosed pleural effusion (i.e. unknown origin).

 The secondary objective of the study is to compare the ability of multiple biomarkers in
 serum and/or pleural fluid combined with pleural fluid cytology and other laboratory results
 to the use of the multiple biomarkers alone to estimate the risk of finding cancer in
 subjects presenting with an undiagnosed pleural effusion.

 The research objectives of the study are the evaluation of the utility of multiple biomarkers
 in serum and/or pleural fluid to predict the tissue of origin in subjects with cancer who
 presented with an undiagnosed pleural effusion and comparison of these results to pleural
 fluid cytology. Correlation of the biomarker levels in the serum and pleural fluid will be
 evaluated as well.
Inclusion Criteria:

 TRAINING SET INCLUSION CRITERIA

 -  Subjects able to understand and sign Informed Consent;

 -  Males or females >18 years of age;

 -  Have a pleural effusion of known or unknown origin;

 -  Scheduled for a diagnostic and/or therapeutic procedure to remove pleural fluid.

 VALIDATION SET INCLUSION CRITERIA

 -  Subjects able to understand and sign Informed Consent;

 -  Males or females >18 years of age;

 -  Have a pleural effusion of unknown origin;

 -  Scheduled for a diagnostic procedure to remove pleural fluid.

 Exclusion Criteria:

 TRAINING SET EXCLUSION CRITERIA

 -  For Subjects currently receiving chemotherapy and/or radiation therapy- Subjects who
 have received chemotherapy and/or radiation therapy must have completed these
 modalities one month before entering the study.

 -  Females known to be pregnant;

 -  Already entered into the study;

 -  Unable or unwilling to provide informed consent or is there a high risk that the
 subject may not comply with the protocol requirements

 VALIDATION SET EXCLUSION CRITERIA

 -  For Subjects currently receiving chemotherapy and/or radiation therapy- Subjects who
 have received chemotherapy and/or radiation therapy must have completed these
 modalities one month before entering the study.

 -  Females known to be pregnant;

 -  Already entered into the study;

 -  Unable or unwilling to provide informed consent or is there a high risk that the
 subject may not comply with the protocol requirements